ArcticZymes AS, a subsidiary company of Biotec Pharmacon ASA, has received a grant of NOK 5 million from the The Research Council of Norway, for a project titled “Functionalization of enzymes from marine bioprospecting”. The total project budget is NOK approx. 10 million over 3 years.
The project is a user driven innovation project which aims to accelerate the commercialization of new functionalized enzyme solutions in the Bioprospecting program under The Research Council’s Biotek2021 initiative.
ArcticZymes’ enzyme portfolio is expanding quickly, primarily due to the progress of strategic partnerships with MabCent, MARZymes and others, and results from the ongoing InnoZymes project which received funding from The Research Council’s Functional Genomics in Norway (FUGE) program in April 2011
MDPI is pleased to announce the publication of the following issue:
Mar. Drugs, Volume 10, Issue 8 (August 2012), Pages Pages 1619-1898
Anthony D. Wright, Jonathan L. Nielson, Dianne M. Tapiolas, Catherine H. Liptrot and Cherie A. Motti
Article: A Great Barrier Reef Sinularia sp. Yields Two New Cytotoxic Diterpenes
Mar. Drugs 2012, 10(8), 1619-1630; doi:10.3390/md10081619
Vânia Cristina Desoti, Danielle Lazarin-Bidóia, Daniela Bueno Sudatti, Renato Crespo Pereira, Antonio Alonso, Tania Ueda-Nakamura, Benedito Prado Dias Filho, Celso Vataru Nakamura and Sueli de Oliveira Silva
Article: Trypanocidal Action of (−)-Elatol Involves an Oxidative Stress Triggered by Mitochondria Dysfunction
Mar. Drugs 2012, 10(8), 1631-1646; doi:10.3390/md10081631
Na Gao, Mingyi Wu, Shao Liu, Wu Lian, Zi Li and Jinhua Zhao
Article: Preparation and Characterization of O-Acylated Fucosylated Chondroitin Sulfate from Sea Cucumber
Mar. Drugs 2012, 10(8), 1647-1661; doi:10.3390/md10081647
Rian J. Meginley, Prasoon Gupta, Thomas C. Schulz, Amanda B. McLean, Allan J. Robins and Lyndon M. West
Article: Briareolate Esters from the Gorgonian Briareum asbestinum
Mar. Drugs 2012, 10(8), 1662-1670; doi:10.3390/md10081662
Vladimir I. Kalinin, Natalia V. Ivanchina, Vladimir B. Krasokhin, Tatyana N. Makarieva and Valentin A. Stonik
Review: Glycosides from Marine Sponges (Porifera, Demospongiae): Structures, Taxonomical Distribution, Biological Activities and Biological Roles
Mar. Drugs 2012, 10(8), 1671-1710; doi:10.3390/md10081671
Malcolm W. B. McCulloch, Brad Haltli, Douglas H. Marchbank and Russell G. Kerr
Article: Evaluation of Pseudopteroxazole and Pseudopterosin Derivatives against Mycobacteriumtuberculosis and Other Pathogens
Mar. Drugs 2012, 10(8), 1711-1728; doi:10.3390/md10081711
Nikolaj G. Vynne, Maria Mansson and Lone Gram
Article: Gene Sequence Based Clustering Assists in Dereplication of Pseudoalteromonas luteoviolacea Strains with Identical Inhibitory Activity and Antibiotic Production
Mar. Drugs 2012, 10(8), 1729-1740; doi:10.3390/md10081729
Laura Núñez-Pons, Marianna Carbone, Jennifer Vázquez, Jaime Rodríguez, Rosa María Nieto, María Mercedes Varela, Margherita Gavagnin and Conxita Avila
Article: Natural Products from Antarctic Colonial Ascidians of the Genera Aplidium and Synoicum: Variability and Defensive Role
Mar. Drugs 2012, 10(8), 1741-1764; doi:10.3390/md10081741
Conceição Egas, Miguel Pinheiro, Paula Gomes, Cristina Barroso and Raul Bettencourt
Article: The Transcriptome of Bathymodiolus azoricus Gill Reveals Expression of Genes from Endosymbionts and Free-Living Deep-Sea Bacteria
Mar. Drugs 2012, 10(8), 1765-1783; doi:10.3390/md10081765
Eliseu Rodrigues, Lilian R. B. Mariutti and Adriana Z. Mercadante
Article: Scavenging Capacity of Marine Carotenoids against Reactive Oxygen and Nitrogen Species in a Membrane-Mimicking System
Mar. Drugs 2012, 10(8), 1784-1798; doi:10.3390/md10081784
Genoveffa Nuzzo, Maria Letizia Ciavatta, Robert Kiss, Véronique Mathieu, Helene Leclercqz, Emiliano Manzo, Guido Villani, Ernesto Mollo, Florence Lefranc, Lisette D’Souza, Margherita Gavagnin and Guido Cimino
Article: Chemistry of the Nudibranch Aldisa andersoni: Structure and Biological Activity of Phorbazole Metabolites
Mar. Drugs 2012, 10(8), 1799-1811; doi:10.3390/md10081799
Bárbara Frazão, Vitor Vasconcelos and Agostinho Antunes
Review: Sea Anemone (Cnidaria, Anthozoa, Actiniaria) Toxins: An Overview
Mar. Drugs 2012, 10(8), 1812-1851; doi:10.3390/md10081812
Shu-Ping Wu, Tsui-Chin Huang, Ching-Chun Lin, Cho-Fat Hui, Cheng-Hui Lin and Jyh-Yih Chen
Article: Pardaxin, a Fish Antimicrobial Peptide, Exhibits Antitumor Activity toward Murine Fibrosarcoma in Vitro and in Vivo
Mar. Drugs 2012, 10(8), 1852-1872; doi:10.3390/md10081852
Tomohiro Osaki, Kazuo Azuma, Seiji Kurozumi, Yoshimori Takamori, Takeshi Tsuka, Tomohiro Imagawa, Yoshiharu Okamoto and Saburo Minami
Article: Metabolomic Analyses of Blood Plasma after Oral Administration of D-Glucosamine Hydrochloride to Dogs
Mar. Drugs 2012, 10(8), 1873-1882; doi:10.3390/md10081873
Tzu-Rong Su, Feng-Jen Tsai, Jen-Jie Lin, Han Hsiang Huang, Chien-Chih Chiu, Jui-Hsin Su, Ya-Ting Yang, Jeff Yi-Fu Chen, Bing-Sang Wong and Yu-Jen Wu
Article: Induction of Apoptosis by 11-Dehydrosinulariolide via Mitochondrial Dysregulation and ER Stress Pathways in Human Melanoma Cells
Mar. Drugs 2012, 10(8), 1883-1898; doi:10.3390/md10081883
Scientists have figured out how to use chitosan — a substance derived from shrimp and crab shells — to delay the ripening of bananas for up to two weeks. Scientists speaking in Philadelphia at the 244th National Meeting & Exposition of the American Chemical Society described experiments designed to develop a spray-on coating that consumers could use themselves.
The coating, a “hydrogel,” is a superabsorbent material made from chitosan. Xihong Li, PhD, who presented the report, noted that chitosan is a great option for the feat because of its action in killing bacteria that cause produce to rot.
Sapphire Energy, Inc., one of the world leaders in algae-based green crude oil production, today announced the first phase of its Green Crude Farm, the world’s first commercial demonstration algae-to-energy facility, is now operational. Construction of this first phase, which began on June 1, 2011, was completed on time and on budget.
When completed, the facility will produce 1.5 million gallons per year of crude oil and consist of approximately 300 acres of algae cultivation ponds and processing facilities. By reaching this key milestone, Sapphire Energy is on target to make algae-based Green Crude a viable alternative fuel solution capable of significantly reducing the nation’s need for foreign crude oil, which will serve as the blueprint for scalable algae biofuel facilities globally.
Shrividya Enterprises, Mumbai, India based manufacturer of Chitin and Protein announced increase in the production capacity: Chitin capacity is increased from 40MT Per year to 60MT per year and Protein capacity increased from 108MT per year to 216MT per year
Chitin is basic raw material for upstream compounds such as ,Glucosamine Sulphate and Chitosan.Chitin Is Extracted from shrimp/ Prawn shells. Chitin is light in weight and white in colour. Shrividya Enterprises is established manufacturer of chitin since 1999. It has a manufacturing facility in Ratnagiri district of Maharashtra, India. Now Shrividya enterprises can supply upto 60MT per year. This increase in capacity will help meet growing customer demand for Chitin.
Nelson’s Cawthron Institute has broken into an international market selling minute quantities of organic compounds sourced from algae and worth 50,000 times the price of gold.
A level teaspoon of the compounds was worth several million dollars, acting chief executive Daryl Wehner said today.
“Our sales over the first nine months have exceeded a quarter of a million dollars and we have several large orders already placed awaiting delivery,” he said.
The compounds, natural toxins produced by algae, often found in food such as shellfish, are necessary for research and other high value products, including pharmaceuticals, making them of special interest to scientists working in these fields, as well as regulatory bodies.
Cawthron is one of only a handful of organisations worldwide with the capability to produce these rare naturally occurring compounds to the market.
Aqua Bio Technology ASA (Oslo Axess: ABT) today announced a partnership with Amway, one of the world’s largest direct sellers, for the use of ABT’s lead marine-derived ingredient Aquabeautine XL® in ARTISTRY® skincare products. ABT expects the agreement to provide revenues of at least NOK 8 million over the next 30 months, with a significant upside potential.
“The agreement with Amway is our most important commercial milestone to date. It confirms the potential of Aquabeautine XL® as a key component in the next generation of skincare products. Furthermore, our relationship with Amway will serve as an important reference as we roll out our new marketing strategy,” said ABT’s CEO Arvid Lindberg.
Michigan, US-based Amway is a worldwide leader in direct selling, with more than three million Independent Business Owners (IBOs) in more than 80 countries and territories around the world. Its ARTISTRY® is among the world’s top five, largest-selling, premium skincare brands.
Some 30 million NOK are to be made available for new initiatives alongside continuing support for established programmes such as MABIT and Marbank.
“We will have the first call for proposals from the new biotech program (BIOTEK2021) in February says special adviser Steinar Bergseth, who has long championed the sector.” Also I am pleased to say that internationally Norway is taking a lead in this area – perhaps only naturally considering our marine traditions and the length of our coastline.
Marinova has some exciting news to report in the area of new clinical trials. Reflecting a commitment to developing novel fucoidan compounds with proven therapeutic efficacy, they have just commenced two new clinical trials. These two studies will investigate the potential of Maritech® fucoidan in the following clinical settings:
• Osteoarthritis and Inflammation
This is a large multi-site trial, directly commissioned by Marinova, to assess the ability of Maritech® fucoidan to reduce the symptoms of osteoarthritis. The trial is double randomised, placebo controlled and – in addition to pain score testing – serum samples will be tested for several key markers of inflammation. This study is being conducted at Southern Cross University (Australia) and results are expected in the second quarter of 2012.
• Integrative Oncology
At two centres in Australia, cancer patients undergoing chemotherapy for breast cancer will take Maritech® fucoidan. The levels of chemotherapy drug in serum will be measured to assess the effects of fucoidan, including any interactions with the chemotherapy drug. Indicators of pain and improvements in quality of life will also be assessed. This study is being conducted in conjunction with the University of Tasmania and is scheduled for completion at the end of 2013.
PetroAlgae Inc. (otcpk:PALG), a global provider of licensed technology that produces micro-crops for renewable protein, feed, and fuel products announced today the completion of the first phases of two studies showing that PetroAlgae micro-crop protein could qualify as the first major new plant protein source for humans since soy protein entered the human diet in the 1950s.
PetroAlgae’s patent pending technology employs a hydroponic system using indigenous aquatic plants and is designed to enable its licensees to produce high-value protein, animal feed and a cost-effective alternative to fossil fuels, while absorbing carbon dioxide. Unlike most soy products, PetroAlgae protein is not produced from genetically modified (GMO) species; it is derived from renewable aquatic crops using no pesticides or heavy metals that would otherwise contaminate the products with residues. Moreover, by using a local, non-GMO species, the PetroAlgae licensed technology preserves the ecological integrity of the areas that are farmed, and it does not pollute soil or water.
The studies were performed at the College of Agriculture at Purdue University, under the direction of Dr. Mario Ferruzzi; by Dr. Fadi Aramouni of the College of Animal Sciences and Industry at Kansas State University; and by independent laboratories such as Craft Technologies, Inc.